NBE-Therapeutics utilizes a portfolio of in-house developed, externally acquired, and in-licensed novel patent families for the development of novel, best-in-class antibody drug conjugates (ADCs), that can specifically target cancer cells for destruction.

Technologiepark Basel
Hochbergerstrasse 60C
4057 Basel

Tel:  +41 61 633 22 30
Fax: +41 61 633 22 31


company website

testimonial about Technologiepark Basel

The Technology Parc Basel provides a thriving environment for high-tech start-up companies, that allows new ventures to benefit from common interests and from a state-of-the art laboratory, office and IT infrastructure.